文献速递泌尿男性生殖肿瘤

TAR-200联合西瑞利单抗对比西瑞利单抗单药新辅助治疗肌层浸润性膀胱癌:SunRISe-4主要分析与生物标志物结果

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
PubMed 文献 · J Clin Oncol · 2025-12-03

SunRISe-4是一项开放标签、多中心、平行队列II期研究,评估TAR-200联合西瑞利单抗对比西瑞利单抗单药新辅助治疗肌层浸润性膀胱癌的疗效与安全性。结果显示联合组pCR、pOR和1年RFS均高于单药组,且utDNA和ctDNA MRD状态与pCR和RFS相关。

要点

  • 联合组pCR 38%、pOR 53%、1年RFS 77%,单药组分别为28%、44%、64%。
  • 联合组pCR在各亚组中一致,未观察到新的安全性信号。
  • RC前utDNA-和utDNA清除与pCR相关,基线和第12周ctDNA-与更长RFS相关。

核心结论

  • TAR-200联合西瑞利单抗较西瑞利单抗单药提高了pCR、pOR和1年RFS率,支持进一步研究该新辅助联合方案。
  • utDNA和ctDNA MRD结果支持进一步研究作为分别检测局部和非局部残留病的生物标志物。

研究设计与样本

  • 开放标签、多中心、平行队列II期研究,纳入cT2-T4a N0M0、不适合或拒绝顺铂新辅助化疗且计划行根治性膀胱切除术的肌层浸润性膀胱癌患者。
  • 患者按5:3随机分配至TAR-200联合西瑞利单抗组(队列1)或西瑞利单抗单药组(队列2),按TURBT完整性和T分期分层。
  • 主要终点为RC时的pCR;次要终点包括RFS和安全性;探索性终点包括pOR和ctDNA/utDNA MRD。
  • 截至2025年5月9日数据截止,共159例患者接受治疗,其中队列1的88例和队列2的46例接受了RC。

主要发现

  • 队列1的pCR、pOR和1年RFS率分别为38%、53%和77%,队列2分别为28%、44%和64%。
  • pCR率在各亚组中一致,未观察到新的安全性信号。
  • RC前(第12周)utDNA-状态和utDNA清除与pCR相关(P < 10^-5和< 10^-3)。
  • 基线和第12周ctDNA-状态与同时点ctDNA+状态相比与更长RFS相关(P = .04和0.01)。

关键数值与推荐

  • 队列1(TAR-200联合西瑞利单抗)pCR 38%、pOR 53%、1年RFS 77%。
  • 队列2(西瑞利单抗单药)pCR 28%、pOR 44%、1年RFS 64%。

临床怎么用

  • 对于不适合或拒绝顺铂新辅助化疗的MIBC患者,TAR-200联合西瑞利单抗新辅助治疗显示较单药更高的pCR和1年RFS,可作为进一步研究的方案。
  • utDNA和ctDNA MRD状态可能有助于评估残留局部和非局部病变,支持作为生物标志物进一步研究。

局限性

  • 本研究为II期、开放标签、平行队列设计,样本量有限,结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Standard of care for muscle-invasive bladder cancer (MIBC) is radical cystectomy (RC) with neoadjuvant cisplatin-based chemotherapy (NAC). However, many patients are ineligible for or refuse cisplatin. SunRISe-4 (ClinicalTrials.gov identifier: NCT04919512) is an open-label, multicenter, parallel-cohort phase II study assessing neoadjuvant gemcitabine intravesical system (TAR-200/gem-iDRS) plus cetrelimab or cetrelimab monotherapy in patients with MIBC. METHODS: Adults with Eastern Cooperative Oncology Group performance status 0-1, cT2-T4a N0M0, ineligible/refusing NAC, and planned for RC were randomly assigned 5:3, stratified by transurethral resection of bladder tumor completeness (residual tumor ≤3 cm permitted) and T stage, to receive TAR-200 plus cetrelimab (cohort 1) or cetrelimab monotherapy (cohort 2). The primary end point was pathologic complete response (pCR) at RC. Secondary end points included recurrence-free survival (RFS) and safety. Exploratory end points included pathologic overall response (pOR; ≤ypT1N0) and circulating tumor (ct) and urinary tumor (ut) DNA molecular residual disease (MRD). Side-by-side descriptive efficacy summary was planned. RESULTS: At the May 9, 2025, data cutoff, 159 patients were treated; 88 in cohort 1 and 46 in cohort 2 underwent RC. pCR, pOR, and 1-year RFS rates were 38%, 53%, and 77% in cohort 1 and 28%, 44%, and 64% in cohort 2, respectively. pCR rates were consistent across subgroups. No new safety signals were observed. Across cohorts, utDNA- status before RC (week 12) and utDNA clearance correlated with pCR (P < 10-5 and < 10-3, respectively). ctDNA- status at baseline and week 12 was associated with longer RFS compared with ctDNA+ status at the same time point (P = .04 and 0.01, respectively). CONCLUSION: TAR-200 plus cetrelimab provided higher pCR, pOR, and 1-year RFS rates compared with cetrelimab monotherapy, supporting further investigation of the neoadjuvant combination in MIBC. utDNA and ctDNA MRD results support further investigation as biomarkers for residual local and nonlocal disease, respectively.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Necchi A, Guerrero-Ramos F, Crispen PL, et al. Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results. J Clin Oncol. 2025. PMID: 41337691. doi:10.1200/JCO-25-02382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。